Biocytogen Entered into a License Agreement with Pheon Therapeutics to Develop Antibody-Drug Conjugate for Cancer
Shots:
- Biocytogen will receive an up front & is eligible to receive development and commercial milestones along with royalties on net sales. Pheon will be responsible to develop & commercialize Ab developed using Biocytogen’s RenMice platforms which feature the complete replacement of human Ab variable genes in situ
- The recent agreement helps to accelerate Pheon’s ADC pipeline which boasts first-in-class & best-in-class ADCs for oncology
- The collaboration will combine Biocytogen’s fully human Ab discovery with Pheon’s strengths in ADC technologies to advance the generation of differentiated novel therapies that provide benefits to patients
Ref: Businesswire| Image: Biocytogen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
